Tempus AI has raised an additional $300 million in incremental debt financing from alternative investment manager Ares Management that is intended to support the firm's recent acquisition of Ambry ...

A: Eric Lefkofsky, CEO, explained that acquiring Ambry provides Tempus with a West Coast lab, complementing existing labs in Chicago, Raleigh, and Atlanta. While there are no immediate plans to ...

According to the firm, the latest acquisition gives Tempus a $300 profitable germline testing lab. Plus, it'll strengthen Tempus AI product offerings and help it expand into new territory.

A technician in a lab coat standing in a cleanroom with energy storage systems in the background. Tempus AI, Inc. (NASDAQ:TEM) is a healthcare technology company that provides polymerase chain ...